News Feature
Adamas Pharma higher after positive Gocovri trial data
February 11, 2020
Adamas Pharmaceuticals (NASDAQ:ADMS) has published trial data indicating its Gocovri has maintained its treatment effect on motor complications for at least two years.
Seeking Alpha